Pfizer shares were down more than 1% Monday afternoon despite the pharmaceutical giant’s report Sunday of successful late-stage trial results for an experimental rheumatoid arthritis drug. The study showed tasocitinib reduced p…
The world’s biggest drugmaker reported earnings of $4.4 billion that topped estimates but revenues of $16.2 billion fell short of expectations.
Continue reading Pfizer Earnings Top Estimates, Boosts Guidance
…
With King in its fold, Pfizer — which makes Lyrica and Celebrex — believes it can build an industry-leading portfolio of pain relievers. Among King’s most appealing entrants in that market is the new Embeda, designed to preve…